

Global Interest is High for Biostar's Stem Cell Treatment of Parkinson's Disease Approved by MHLW of Japan

LOS ANGELES, CA, UNITED STATES, May 21, 2024 /EINPresswire.com/ -- Biostar StemCell Research Institute's stem cell treatment for Parkinson's disease is increasing in global attention post Japan's regulatory approval.

Kudo Clinic in Tokyo signed on management of Parkinson's disease patients through the effectiveness, safety, and continuous evaluation of stem cell treatment

Upon obtaining regulatory approval for treatment of Parkinson's disease from the Japanese Ministry of Health and Welfare, treatment of Parkinson's disease has begun. A worldwide interest in this treatment technology developed by Biostar StemCell Research Institute has been growing.



Kudo Clinic in Tokyo

The number of inquiries on this treatment are not only increasing from Asia, but also from India, the United States, Africa, and Israel. Patients are currently traveling from the United States, Turkey, and the United Kingdom to Shinjuku Clinic in Tokyo, Japan to receive treatment for Parkinson's disease.

Accordingly, Biostar StemCell Research Institute and its affiliate, JASC (Japan Angel StemCell) have decided to improve patient care services to raise medical services on a global level. JASC has signed a contract with Kudo Clinic to establish a patient-centered treatment environment.

Kudo Clinic is a neurosurgery clinic which was first operated by Dr. Chiaki Kudo who is a neurosurgeon. The clinic has been a specialized treatment institution for patient with brain diseases such as Parkinson's disease, dementia, and migraines since 2001.

Professional patient management medical services will be provided at Kudo Clinic. These medical services will be examined through brain MRI, MDS-UPDRS (Unified Parkinson's Disease Rating Scale), and neurological examinations, which consistently evaluate the safety and efficacy of intravenous and intrathecal injections of stem cells. These methods are expected to play an important role in building a patient-centered treatment environment.

These medical services are expected not only to provide new hope for patients with Parkinson's disease, but also to position themselves as the model practices for medical innovation and disease management in stem cell therapy worldwide.

Based on the treatment experience in Japan, Biostar StemCell Research Institute, together with Nature Cell Co. Ltd., plans to prepare for the commercialization of advanced regenerative medical treatment technology for Parkinson's disease patients in Korea and launch the services in Korea by 2025.

Sunyoung Kim
Biostar StemCell Research Institute
+1 424-227-9568
kimsun@rbio.co.kr

This press release can be viewed online at: <https://www.einpresswire.com/article/713507479>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.